Camson Bio Technologies Limited announced unaudited standalone earnings results for the third quarter and nine months ended December 31, 2017. For the quarter, the company reported revenue from operations of INR 38.534 million compared with INR 53.855 million for the same period a year ago. Loss before exceptional items and tax and loss before tax was INR 55.840 million compared with INR 101.085 million for the same period a year ago. Net loss was INR 55.840 million or INR 1.86 per basic and diluted share compared with INR 97.172 million or INR 3.24 per basic and diluted share for the same period a year ago. For the nine months, the company reported revenue from operations of INR 198.196 million compared with INR 96.267 million for the same period a year ago. Loss before exceptional items and tax and loss before tax was INR 63.139 million compared with INR 221.592 million for the same period a year ago. Net loss was INR 63.139 million or INR 2.10 per basic and diluted share compared with INR 221.029 million or INR 7.37 per basic and diluted share for the same period a year ago.